Be part of the knowledge.™

Oncology and Hematology

1515

LikeLikedUnlike

31-45 of 773

Conquering the Burden & Impacts of PNH
Project Oncology®
Conquering the Burden & Impacts of PNH
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Hana Safah, MD
  Peer
- Timothy Kubal, MD
  Peer
Improving PNH Patient Outcomes
Project Oncology®
Improving PNH Patient Outcomes
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- David Dingli, MD, PhD
  Peer
Examining the Treatment Paradigm for Paroxysmal Nocturnal Hemoglobinuria
Project Oncology®
Examining the Treatment Paradigm for Paroxysmal Nocturnal Hemoglobinuria
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Brian Mulherin, MD
  Peer
Managing PNH Patients: Addressing the Unmet Needs
Project Oncology®
Managing PNH Patients: Addressing the Unmet Needs
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Brian Mulherin, MD
  Peer
Navigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
Heart Matters
Navigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
- Jun-ichi Abe, MD, PhD
  Peer
10-Year PORTEC-3 Outcomes: Chemoradiotherapy in High-Risk Endometrial Cancer
Project Oncology®
10-Year PORTEC-3 Outcomes: Chemoradiotherapy in High-Risk Endometrial Cancer
advertisement
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Project Oncology®
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
- Ryan Quigley
  Peer
Predicting Prognosis in DLBCL: The Role of Immune-Related Gene Signatures
Project Oncology®
Predicting Prognosis in DLBCL: The Role of Immune-Related Gene Signatures
Refining Risk, Reducing Burden: ENDORISK-2 and Preoperative Stratification in Endometrial Cancer
Project Oncology®
Refining Risk, Reducing Burden: ENDORISK-2 and Preoperative Stratification in Endometrial Cancer
Relapsed or Refractory DLBCL: Reviewing the Expanding Treatment Landscape
Project Oncology®
Relapsed or Refractory DLBCL: Reviewing the Expanding Treatment Landscape
Real-World CDK4/6 Inhibitor Patterns in HR+/HER2– Metastatic Breast Cancer
Project Oncology®
Real-World CDK4/6 Inhibitor Patterns in HR+/HER2– Metastatic Breast Cancer
- Pavani Chalasani, MD, MPH
  Peer
- Adam Brufsky, MD, PhD
  Peer
Selecting First-Line Therapy in Gastric Cancers: A Biomarker-Driven Approach
Project Oncology®
Selecting First-Line Therapy in Gastric Cancers: A Biomarker-Driven Approach
- Jennifer Caudle, DO
  Peer
- Samuel Klempner, MD
  Peer
- Nataliya Uboha, MD, PhD
  Peer
advertisement
Assessing Atirmociclib Plus Letrozole in HR+/HER2- Metastatic Breast Cancer
Project Oncology®
Assessing Atirmociclib Plus Letrozole in HR+/HER2- Metastatic Breast Cancer
- Pavani Chalasani, MD, MPH
  Peer
- Antonio Giordano, MD, PhD
  Peer
Axatilimab for cGVHD: Assessing Organ-Specific Responses in AGAVE-201
Project Oncology®
Axatilimab for cGVHD: Assessing Organ-Specific Responses in AGAVE-201
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Shernan Holtan, MD
  Peer
- Alicia Lieberman, MD, MS
  Peer
Obesity and Cancer Screening: National Trends and Disparities Revealed
Clinician's Roundtable
Obesity and Cancer Screening: National Trends and Disparities Revealed
- Vance Albaugh, MD, PhD
  Peer

Program Chapters

Segment Chapters

Playlist:

Recommended